Synergistic Cholestatic Disease Treatment Systems

The present inventive concept integrates the patented methods of treating cholestatic diseases with cutting-edge technologies such as AI, IoT, blockchain, and genomics analysis to create a more effective, personalized, and secure treatment system.

The original patent disclosed methods for treating cholestatic diseases, specifically PBC and PSC. However, these methods have limitations in terms of patient data management, treatment efficacy prediction, and personalized treatment plans. The new inventive concept addresses these limitations by leveraging synergistic combinations of technologies to create a more comprehensive and effective treatment system.

The new inventive concept comprises a blockchain-based patient data management platform, machine learning algorithms for predicting treatment efficacy, AI-powered genomics analysis software, IoT-enabled sensors for tracking biomarkers, and cloud-based data analytics platforms for identifying trends and patterns. These components work together to provide personalized treatment plans, optimize treatment options, and ensure secure and transparent storage of patient data. The system can be integrated with wearable devices for monitoring patient symptoms, and electronic health records can be securely stored on a blockchain-based platform.

The new claims introduce a novel combination of technologies that creates a more powerful and effective treatment system for cholestatic diseases. The integration of AI, IoT, blockchain, and genomics analysis with the patented methods of treating cholestatic diseases provides a non-obvious and innovative solution that addresses the limitations of the original patent.

Alternative embodiments of the inventive concept could include the use of different machine learning algorithms, varying IoT sensor configurations, or alternative blockchain platforms. Additionally, the system could be adapted for use in treating other diseases or conditions, or integrated with other healthcare technologies such as telemedicine platforms or medical imaging devices.

The synergistic cholestatic disease treatment system has significant commercial potential in the healthcare industry, particularly in the areas of personalized medicine, disease management, and healthcare data analytics. The system could be marketed to healthcare providers, pharmaceutical companies, and medical research institutions, and could potentially disrupt the current treatment paradigm for cholestatic diseases.